Showing results (21-30 of 159) with videos related to
Sort By:
Pageof 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2012
Phospho-specific flow: fixating on the targetMark LevisHematology. American Society of Hematology. Education Program|December 5, 2025
Post-HCT maintenance therapy for AML: who, when, why, how long?Mark LevisBest Practice & Research. Clinical Haematology|March 25, 2021
Is there evidence for the use of FLT3 inhibitors as maintenance therapy in AML?Mark LevisFuture Oncology (London, England)|August 23, 2014
Quizartinib for the treatment of FLT3/ITD acute myeloid leukemiaMark LevisMayo Clinic Proceedings|January 26, 2005
Large cell carcinoma with calcitonin and vasoactive intestinal polypeptide-associated Verner-Morrison syndromeKeith W Pratz, Cynthia Ma, Marie-Christine Aubry, et al.Current Opinion in Hematology|January 20, 2011
FLT3 inhibitors: a story of the old and the newAmir Fathi, Mark LevisExpert Opinion on Investigational Drugs|December 4, 2003
Novel FLT3 tyrosine kinase inhibitorsMark Levis, Donald SmallInternational Journal of Hematology|September 9, 2005
FLT3 tyrosine kinase inhibitorsMark Levis, Donald SmallCurrent Pharmaceutical Design|April 14, 2004
Small molecule FLT3 tyrosine kinase inhibitorsMark Levis, Donald SmallExpert Opinion on Therapeutic Targets|September 19, 2014
Targeting FLT3 to treat leukemiaHeiko Konig, Mark LevisPageof 16